 SOMERVILLE, Mass., May 28, 2021 GLOBE NEWSWIRE -- Finch Therapeutics Group, Inc. Finch or Finch Therapeutics Nasdaq: FNCH, a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in two upcoming virtual investor conferences: 